Alzheimer's Disease Program September 28 - Open to Everyone
Join us on September 28 at 11:30am during our normal VIP Brown Bag Lunch time to learn more about Alzheimer's and the latest treatment options.
We'll enjoy a 30 minute talk on Alzheimer's and a time of Q & A in room 25.
The Presentation: CAN ALZHEIMER’S BE STOPPED?
This program will give an update on Alzheimer’s Disease, what causes it, how it is currently treated, and how it affects patients and their families. It will explore Dr. Alzheimer’s first patient with what he called a disease of forgetfulness in 1901 and how what he learned back then is now the focus of new treatments which are showing an ability to stop the progression of Alzheimer’s. It will explore what we currently understand to be happening in the brain of affected patients and just how these changes produce the symptoms of the disease. Finally, it will review current treatment options that can delay and diminish the disease but importantly what treatment may be on the horizon from the research arena. At the end, we will answer the question: Can Alzheimer’s Be Stopped?
Format: lecture with power point slides (or alternatively a handout of slides) which can be delivered in 30-35 minutes (or a little as 15 minutes) followed by questions and answers.
Option: If desired, a 60 minute NOVA program by the same name can be shown followed by an abbreviated lecture and audience discussion requiring 90 minutes.
An informational brochure, written by the presenter, will be provided to all attendees.
The Speaker: Dr. James M. McKenney
James M. McKenney, PharmD, is president and CEO of National Clinical Research and the Alzheimer’s Research Center, both in Richmond, Virginia. He is also Professor Emeritus of the Virginia Commonwealth University School of Pharmacy in Richmond where he was a faculty member for 30 years. Dr. McKenney is a graduate of Hampton Sydney College, the Medical College of Virginia, and Wayne State University in Detroit, Michigan. He has spent his life studying new medications used to treat common illnesses. His research and practice focus has been on the treatment of cardiovascular disease and more recently, Alzheimer’s Disease. He helped write national guidelines for use by doctors throughout the country to treat high blood cholesterol as a means of reducing heart disease. He was a founding member and past President of the National Lipid Association. He has received many awards from national organizations for his contribution to the fields of cardiovascular treatments. Dr. McKenney has published more than 200 original research articles and many other articles and book chapters dealing with heart disease and has directed more than 1000 clinical trials evaluating new treatments for common illnesses.